General Information of the Drug (ID: M6ADRUG0067)
Name
Arsenite
Synonyms
Sodium metaarsenite; Sodium dioxoarsenate; sodium;oxoarsinite; Arsenite, sodium; UNII-48OVY2OC72; NaAsO2; Sodium (meta)arsenite; 48OVY2OC72; CHEBI:29678; Arsenenous acid, sodium salt (1:1); Prodalumnol; Sodanit; Penite; Kill-All; Prodalumnol double; Rat Death Liquid; Chem Pels C; sodium meta-arsenite; Chem-Sen 56; Caswell No. 744; MFCD00003472; Atlas A; Arsenite de sodium; Arsenenous acid, sodium salt; Arsenite de sodium [French]; Arsenious acid, monosodium salt; CCRIS 5554; HSDB 693; EINECS 232-070-5; EPA Pesticide Chemical Code 013603; Sodium arsenenite; AsO2.Na; (NaAsO2)n; CHEMBL1909078; DTXSID5020104; Sodium (meta)arsenite, >=90%; 5497AF; AKOS025295751; Na(+)n-(-As(O(-))O-)-n; Sodium (meta)arsenite, p.a., 98.0%; catena-poly[(oxidoarsenate-mu-oxido)]sodium; Sodium arsenite, 0.1N Standardized Solution; Sodium arsenite, 0.5M standardized solution; Q419586
    Click to Show/Hide
Status Phase 2 [1]
Structure
3D MOL
Formula
AsNaO2
InChI
InChI=1S/AsHO2.Na/c2-1-3;/h(H,2,3);/q;+1/p-1
InChIKey
PTLRDCMBXHILCL-UHFFFAOYSA-M
PubChem CID
443495
Full List of m6A Targets Related to This Drug
Cellular tumor antigen p53 (TP53/p53)
In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary METTL3 significantly decreased m6A level, restoring Cellular tumor antigen p53 (TP53/p53) activation and inhibiting cellular transformation phenotypes in the arsenite-transformed cells. m6A downregulated the expression of the positive p53 regulator, PRDM2, through the YTHDF2-promoted decay of PRDM2 mRNAs. m6A upregulated the expression of the negative p53 regulator, YY1 and MDM2 through YTHDF1-stimulated translation of YY1 and MDM2 mRNA. This study further sheds light on the mechanisms of arsenic carcinogenesis via RNA epigenetics.
Responsed Disease Solid tumour/cancer ICD-11: 2A00-2F9Z
Target Regulator YTH domain-containing family protein 1 (YTHDF1) READER
Target Regulation Down regulation
Pathway Response p53 signaling pathway hsa04115
In-vitro Model HaCaT Normal Homo sapiens CVCL_0038
Experiment 2 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary METTL3 significantly decreased m6A level, restoring Cellular tumor antigen p53 (TP53/p53) activation and inhibiting cellular transformation phenotypes in the arsenite-transformed cells. m6A downregulated the expression of the positive p53 regulator, PRDM2, through the YTHDF2-promoted decay of PRDM2 mRNAs. m6A upregulated the expression of the negative p53 regulator, YY1 and MDM2 through YTHDF1-stimulated translation of YY1 and MDM2 mRNA. This study further sheds light on the mechanisms of arsenic carcinogenesis via RNA epigenetics.
Responsed Disease Solid tumour/cancer ICD-11: 2A00-2F9Z
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
Target Regulation Up regulation
Pathway Response p53 signaling pathway hsa04115
In-vitro Model HaCaT Normal Homo sapiens CVCL_0038
PR domain zinc finger protein 2 (PRDM2)
In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary METTL3 significantly decreased m6A level, restoring p53 activation and inhibiting cellular transformation phenotypes in the arsenite-transformed cells. m6A downregulated the expression of the positive p53 regulator, PR domain zinc finger protein 2 (PRDM2), through the YTHDF2-promoted decay of PRDM2 mRNAs. m6A upregulated the expression of the negative p53 regulator, YY1 and MDM2 through YTHDF1-stimulated translation of YY1 and MDM2 mRNA. This study further sheds light on the mechanisms of arsenic carcinogenesis via RNA epigenetics.
Responsed Disease Solid tumour/cancer ICD-11: 2A00-2F9Z
Target Regulator YTH domain-containing family protein 1 (YTHDF1) READER
Target Regulation Down regulation
Pathway Response p53 signaling pathway hsa04115
In-vitro Model HaCaT Normal Homo sapiens CVCL_0038
Experiment 2 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary METTL3 significantly decreased m6A level, restoring p53 activation and inhibiting cellular transformation phenotypes in the arsenite-transformed cells. m6A downregulated the expression of the positive p53 regulator, PR domain zinc finger protein 2 (PRDM2), through the YTHDF2-promoted decay of PRDM2 mRNAs. m6A upregulated the expression of the negative p53 regulator, YY1 and MDM2 through YTHDF1-stimulated translation of YY1 and MDM2 mRNA. This study further sheds light on the mechanisms of arsenic carcinogenesis via RNA epigenetics.
Responsed Disease Solid tumour/cancer ICD-11: 2A00-2F9Z
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
Target Regulation Up regulation
Pathway Response p53 signaling pathway hsa04115
In-vitro Model HaCaT Normal Homo sapiens CVCL_0038
References
Ref 1 Sodium meta-arsenite induces reactive oxygen species-dependent apoptosis, necrosis, and autophagy in both androgen-sensitive and androgen-insensitive prostate cancer cells. Anticancer Drugs. 2014 Jan;25(1):53-62. doi: 10.1097/CAD.0000000000000013.
Ref 2 N(6)-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation. Environ Pollut. 2020 Apr;259:113908. doi: 10.1016/j.envpol.2019.113908. Epub 2020 Jan 7.